The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly
heterogeneous patient population and therefore poses unique challenges for therapeutic …

Downstaging can facilitate liver transplantation (LT) for patients outside of Milan criteria with
hepatocellular carcinoma (HCC); however, the optimal protocol and downstaging outcomes …

Purpose A multidisciplinary expert panel convened to formulate state-of-the-art
recommendations for optimisation of selective internal radiation therapy (SIRT) with yttrium …

Transarterial radioembolization (TARE) with yttrium 90 has increasingly been performed to
treat hepatocellular carcinoma (HCC). TARE was historically used as a palliative lobar …

Purpose To further improve the effectiveness and prognosis of primary hepatocellular
carcinoma (HCC) with portal vein tumor thrombus (PVTT), the current status of treatment for …

Abstract Background & Aims To compare selective internal radiation therapy (SIRT) with
transarterial chemoembolization (TACE), the standard‐of‐care for intermediate‐stage …

Hepatocellular carcinoma (HCC) is the sixth-most common malignancy diagnosed
worldwide. 1 Late-stage presentation, comorbidities, and limited donor availability enables …

The high mortality rate associated with hepatocellular carcinoma (HCC) is partly due to the
high proportion of patients who present with advanced stage disease at diagnosis, for whom …

In patients with liver malignancies potentially amenable to curative extended right
hepatectomy but insufficient size of the future liver remnant (FLR), portal vein embolization …

Transarterial chemoembolization (TACE) and radioembolization (RE) are frequently used to
treat patients with hepatocellular carcinoma who cannot receive curative therapies …